United Therapeutics Corporation
US ˙ NasdaqGS ˙ US91307C1027

SecurityUTHR / United Therapeutics Corporation
InstitutionPolianta Ltd
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Polianta Ltd closes position in UTHR / United Therapeutics Corporation

On April 16, 2026 - Polianta Ltd filed a 13F-HR form disclosing ownership of 0 shares of United Therapeutics Corporation (US:UTHR) valued at $0 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 15, 2026 disclosing 3,100 shares of United Therapeutics Corporation. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-16 2026-03-31 13F United Therapeutics Common Stock 91307C102 0 -100.00 0
2026-01-15 2025-12-31 13F United Therapeutics Common Stock 91307C102 3,100 -800 -20.51 2 0.00 0.1976
2025-10-16 2025-09-30 13F United Therapeutics Common Stock 91307C102 3,900 0 0.00 2 0.00 0.6730
2025-07-10 2025-06-30 13F United Therapeutics Common Stock 91307C102 3,900 0 0.00 1 0.00 0.4826
2025-04-16 2025-03-31 13F United Therapeutics Common Stock 91307C102 3,900 3,900 1 0.5803
2022-07-19 2022-06-30 13F United Therapeutics Common Stock 91307C102 0 -5,000 -100.00 0 -100.00
2022-04-20 2022-03-31 13F United Therapeutics Common Stock 91307C102 5,000 5,000 897 0.5872
2022-01-18 2021-12-31 13F United Therapeutics Common Stock 91307C102 0 -6,300 -100.00 0 -100.00
2021-10-19 2021-09-30 13F/A-1 United Therapeutics Common Stock 91307C102 6,300 6,300 1,162 0.5389
2021-10-19 2021-09-30 13F United Therapeutics Common Stock 91307C102 6,300 6,300 1,162 0.5389
2021-04-14 2021-03-31 13F United Therapeutics Common Stock 91307C102 0 -8,900 -100.00 0 -100.00
2021-01-13 2020-12-31 13F United Therapeutics Common Stock 91307C102 8,900 -1,800 -16.82 1,350 25.00 0.7458
2020-10-07 2020-09-30 13F United Therapeutics Common Stock 91307C102 10,700 10,700 1,080 0.6389
2017-04-11 2017-03-31 13F United Therapeutics Common Stock 91307C102 0 -8,100 -100.00 0 -100.00
2017-02-06 2016-12-31 13F United Therapeutics Common Stock 91307C102 8,100 8,100 1,161 0.6278
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.